Shenzhen Hepalink Pharmaceutical Group has been granted a patent for a novel pharmaceutical composition combining berberine with EPA and DHA for treating various diseases. The softgel capsule contains these components along with a pharmaceutically acceptable carrier. The invention aims to address metabolic diseases, liver disorders, heart diseases, inflammation, and cancers. GlobalData’s report on Shenzhen Hepalink Pharmaceutical Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Shenzhen Hepalink Pharmaceutical Group, Transgenic murine models was a key innovation area identified from patents. Shenzhen Hepalink Pharmaceutical Group's grant share as of January 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
Pharmaceutical composition for treating metabolic diseases and liver disorders
A recently granted patent (Publication Number: US11883539B2) discloses a softgel capsule designed to deliver a unit dose of a pharmaceutical composition. The composition includes berberine (BBR) in the form of a chloride, sulfate, or citrate salt, along with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) or their ethyl esters. The capsule also contains a pharmaceutically acceptable excipient, carrier, or diluent to ensure stability and efficacy.
Specific embodiments outlined in the patent claims include variations in the form of BBR salt present, with options for chloride, sulfate, or citrate. The weight ratio of BBR to EPA/DHA in the composition ranges from about 1:1 to 1:8, offering flexibility in dosage formulations. Additionally, the unit dosage form of the capsule includes BBR in the range of 100 mg to 300 mg and EPA/DHA in the range of 100 mg to 800 mg, providing a standardized and convenient delivery method for the pharmaceutical composition. Overall, this patented softgel capsule offers a novel and potentially effective way to administer a combination of BBR, EPA, and DHA for various therapeutic applications.
To know more about GlobalData’s detailed insights on Shenzhen Hepalink Pharmaceutical Group, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
